Publications in collaboration with researchers from Harvard Medical School (32)

2023

  1. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma

    Annals of Oncology

  2. Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up

    Annals of Oncology, Vol. 34, Núm. 3, pp. 289-299

  3. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

    European Urology

  4. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

    European Journal of Cancer

  5. Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma

    European Urology

2022

  1. Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma

    Clinical Genitourinary Cancer, Vol. 20, Núm. 5, pp. e440-e452

  2. Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer

    BJU International, Vol. 130, Núm. 5, pp. 592-603

  3. Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma

    Clinical Genitourinary Cancer, Vol. 20, Núm. 6, pp. 558-567

  4. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma

    Cancer, Vol. 128, Núm. 11, pp. 2085-2097

  5. Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials

    Clinical Cancer Research, Vol. 28, Núm. 10, pp. 2050-2060

  6. Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin

    Clinical Genitourinary Cancer, Vol. 20, Núm. 2, pp. 165-175

2021

  1. A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors

    European urology oncology, Vol. 4, Núm. 3, pp. 464-472

  2. A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy

    European Urology Focus, Vol. 7, Núm. 5, pp. 1130-1136

  3. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial

    The Lancet Oncology, Vol. 22, Núm. 4, pp. 525-537

  4. Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study

    Journal of Clinical Oncology, Vol. 39, Núm. 33, pp. 3725-3736

  5. Enfortumab vedotin in previously treated advanced urothelial carcinoma

    New England Journal of Medicine, Vol. 384, Núm. 12, pp. 1125-1135

  6. Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes

    BJU International, Vol. 128, Núm. 2, pp. 196-205

  7. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma

    Nature, Vol. 595, Núm. 7867, pp. 432-437

2020

  1. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

    The Lancet, Vol. 395, Núm. 10241, pp. 1907-1918

  2. Corrigendum to ‘EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees’ [European Urology 77 (2020) 223–250](S0302283819307638)(10.1016/j.eururo.2019.09.035)

    European Urology